AC Immune Company Insiders

AC Immune Management Team Effectiveness

The company has return on total asset (ROA) of (0.2197) % which means that it has lost $0.2197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7463) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2026. Return On Capital Employed is likely to drop to -0.38 in 2026. At this time, AC Immune's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 21.5 M in 2026, whereas Liabilities And Stockholders Equity is likely to drop slightly above 183.9 M in 2026. Common Stock Shares Outstanding is likely to drop to about 73.9 M in 2026. Net Loss is likely to gain to about (60.5 M) in 2026AC Immune secures a total of 100.6 Million outstanding shares. AC Immune shows tangible amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it. Dividends Paid is likely to gain to 8,452 in 2026. Dividend Paid And Capex Coverage Ratio is likely to gain to 108.02 in 2026. Common Stock Shares Outstanding is likely to drop to about 73.9 M in 2026. Net Loss is likely to gain to about (60.5 M) in 2026.

AC Immune Workforce Comparison

AC Immune Benchmark Summation

AC Immune Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as AC Immune often depends on how effective the management is. AC Immune management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ACIU management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ACIU management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in AC Immune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AC Immune. Check AC Immune's Beneish M Score to see the likelihood of AC Immune's management manipulating its earnings.

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.